Silexion Therapeutics (SLXN) News Today $1.04 +0.05 (+5.51%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.95 -0.09 (-8.65%) As of 05/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock SLXN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Silexion's SIL204 Completes Key Preclinical Studies In KRAS-Mutant CancersMay 23 at 7:31 PM | nasdaq.comSilexion Therapeutics Receives Nasdaq Delisting NoticeMay 23 at 5:55 PM | tipranks.comPESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer TreatmentMay 22 at 3:46 PM | globenewswire.comSilexion Therapeutics Corporation Registered ShsMay 22 at 11:11 AM | markets.businessinsider.comSilexion Therapeutics Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung CancerMay 21, 2025 | finance.yahoo.comSilexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung CancerMay 21, 2025 | globenewswire.comFinancial Survey: Silexion Therapeutics (NASDAQ:SLXN) vs. Tourmaline Bio (NASDAQ:TRML)May 16, 2025 | americanbankingnews.comSilexion Therapeutics Corp: Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | finanznachrichten.deSilexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comSilexion Therapeutics enters collaboration with CatalentApril 25, 2025 | markets.businessinsider.comSilexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing ActivitiesApril 23, 2025 | globenewswire.comSilexion Therapeutics announces expanded development plan for SIL204March 28, 2025 | markets.businessinsider.comSilexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical DataMarch 28, 2025 | globenewswire.comSilexion announces completion of expanded development plan for SIL204March 21, 2025 | markets.businessinsider.comSilexion Therapeutics price target lowered to $5 from $9 at MaximMarch 21, 2025 | markets.businessinsider.comSilexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer ConferenceMarch 21, 2025 | globenewswire.comSilexion Therapeutics Corp: Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateMarch 19, 2025 | finanznachrichten.deSilexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateMarch 18, 2025 | globenewswire.comSilexion Therapeutics Reports Positive Data From SIL204 In Pancreatic Cancer ModelsMarch 7, 2025 | nasdaq.comSilexion reports initial data from systemic administration of SIL204March 5, 2025 | markets.businessinsider.comSilexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer ModelsMarch 5, 2025 | globenewswire.comPESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be TransformationalMarch 3, 2025 | tmcnet.comSilexion completes initial study of SIL-204 in pancreatic cancer modelsFebruary 26, 2025 | markets.businessinsider.comSilexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204February 25, 2025 | globenewswire.comGoldman Sachs Group Inc's Strategic Acquisition in Silexion Therapeutics CorpFebruary 10, 2025 | gurufocus.comSilexion Therapeutics (SLXN) Gets a Buy from Maxim GroupJanuary 31, 2025 | markets.businessinsider.comSLXNW Silexion Therapeutics Corp Wt ExpJanuary 29, 2025 | seekingalpha.comSilexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross ProceedsJanuary 29, 2025 | globenewswire.comSilexion Therapeutics reports preclinical data for SIL-204January 28, 2025 | markets.businessinsider.comSilexion reports breakthrough in KRAS cancer therapyJanuary 28, 2025 | msn.comSilexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer ModelsJanuary 28, 2025 | globenewswire.comSLXN stock touches 52-week low at $0.82 amid sharp annual declineJanuary 22, 2025 | msn.comPESG Market Update: Silexion Therapeutics’ SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer TreatmentsJanuary 17, 2025 | finance.yahoo.comSilexion Stock Hits Record Intraday Low After Pricing $5M Offering, But Retail Excitement Over Cancer Data EnduresJanuary 16, 2025 | msn.comPESG Market Update: Silexion Therapeutics' SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer TreatmentsJanuary 16, 2025 | businesswire.comSilexion Therapeutics Shares Jump After Pancreatic-Cancer Treatment DataJanuary 16, 2025 | marketwatch.comSilexion Therapeutics announces new preclinical results for SIL-204January 16, 2025 | markets.businessinsider.comSilexion Therapeutics Announces Pricing of $5.0 Million Public OfferingJanuary 15, 2025 | globenewswire.comSilexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer ChemotherapiesJanuary 15, 2025 | globenewswire.comSilexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers SymposiumJanuary 13, 2025 | globenewswire.comSilexion Therapeutics, Evonik collaborate on siRNA formulation developmentDecember 18, 2024 | finance.yahoo.comSilexion Therapeutics collaborates with Evonik on advanced siRNA Formulation DevelopmentDecember 17, 2024 | markets.businessinsider.comPESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions RisesDecember 17, 2024 | businesswire.comSilexion Therapeutics appoints Peled to board of directorsDecember 11, 2024 | markets.businessinsider.comSilexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of DirectorsDecember 10, 2024 | markets.businessinsider.comSilexion Therapeutics Corp trading halted, news pendingNovember 27, 2024 | tipranks.comSilexion Therapeutics Corp: Silexion Therapeutics Announces 1-for-9 Reverse Share SplitNovember 23, 2024 | finanznachrichten.deSilexion Therapeutics Announces 1-for-9 Reverse Share SplitNovember 22, 2024 | globenewswire.com5 Stocks Retail Investors Are Most Bullish On At Mid-DayNovember 20, 2024 | msn.comWhat's Going On With Silexion Therapeutics Shares Wednesday?November 20, 2024 | benzinga.com Get Silexion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLXN and its competitors with MarketBeat's FREE daily newsletter. Email Address SLXN Media Mentions By Week SLXN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLXN News Sentiment▼-0.280.77▲Average Medical News Sentiment SLXN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLXN Articles This Week▼61▲SLXN Articles Average Week Get Silexion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLXN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SCYNEXIS News Dyadic International News FibroGen News Marinus Pharmaceuticals News Grace Therapeutics News Cadrenal Therapeutics News MiNK Therapeutics News Allakos News OnKure Therapeutics News Kezar Life Sciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLXN) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silexion Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Silexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SLXN Stock Free SLXN Stock Alerts